Literature DB >> 238814

Metabolism of propionyl erythromycin lauryl sulfate. I. Fate of the propionyl erythromycin moiety in the rat.

P J Murphy, T L Williams, R E McMahon, F J Marshall.   

Abstract

The absorption, excretion, and metabolism of propionyl erythromycin (PE) has been studied in the rat. The major routes of metabolism of PE are ester hydrolysis and N-demethylation. The rates of these two reactions have been examined in vivo using radiolabeled PE. The plasma half-life of the ester is 5.5 hr. The correlation of blood levels of radioactivity with 14CO2 production indicates that the ester is continually hydrolyzed after absorption. The half-life of the dimethyl-amino moiety of the desosamine sugar is estimated at 1.5 hr. This relatively short half-life compared to that of the ester is supported by the fact that at 3.5 hr after dosing there is twice as much desmethyl-PE in plasma as PE. After oral administration of either 14C-PE or 14C-erythromycin, 70% of the radioactivity is absorbed in 6 hr. The major route of excretion is via bile. Approximatley 40% of the absorbed dose is excreted in bile in the first 6 hr after dosing. Tissue levels of radioactivity after administration of 14C-erythromycin or 14C-PE indicate that PE or a metabolite accumulates in the tissue during chronic dosing, whereas erythromycin-related levels are similar after single or multiple doses.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 238814

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  4 in total

1.  Autobacteriographic studies of clarithromycin and erythromycin in mice.

Authors:  Y Kohno; K Ohta; T Suwa; T Suga
Journal:  Antimicrob Agents Chemother       Date:  1990-04       Impact factor: 5.191

2.  Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man.

Authors:  P B Watkins; S A Wrighton; E G Schuetz; D T Molowa; P S Guzelian
Journal:  J Clin Invest       Date:  1987-10       Impact factor: 14.808

3.  Therapeutic doses of erythromycin esteolate is not cholestatic in rats in vivo.

Authors:  I Fiebiger; M S Anwer; D Hegner
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-05       Impact factor: 3.000

4.  Comparative pharmacokinetics of clarithromycin (TE-031), a new macrolide antibiotic, and erythromycin in rats.

Authors:  Y Kohno; H Yoshida; T Suwa; T Suga
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.